EUR/USD
1.14011
-0.124%
Gold
4053.99
-1.323%
Oil
74.359
4.039%
USD/JPY
162.010
0.174%
GBP/USD
1.33798
-0.134%
GBP/JPY
216.771
0.039%
Real-time News
The Jordanian military said it intercepted and shot down four missiles that entered its airspace from Iran.July 13 – As a $1.8 trillion rally that propelled Asian chipmakers to the ranks of the worlds largest companies begins to reverse, investors are cutting back on bets on Asian chip stocks, raising concerns about their excessive weighting in emerging market indices. Funds such as Fidelity International and BlackRock are expressing concern about the sustainability of the bull run in stocks like SK Hynix and Samsung Electronics. Over the past six months, the combined market capitalization of these three companies has nearly doubled, and their combined weighting in the MSCI Emerging Markets Index is now approximately 29%, exceeding the weighting of most single countries. Caroline Shaw, multi-asset portfolio manager at Fidelity International, stated that the high concentration of the index, coupled with the significant increase in leveraged bets on South Korean chip stocks amplifying price volatility, are "worrying signs." In the MSCI Emerging Markets Index, the weighting of these three stocks is currently almost three times the total weighting of all Indian stocks, and SK Hynix alone has a weighting exceeding the combined weighting of Brazil and South Africa. Wei Li, global chief investment strategist at BlackRock Investment Institute, said the firm is “happy to take profits at this stage” and reduce its overweight position in emerging market stocks relative to benchmarks due to the volatility in some large chip and memory stocks.According to the Financial Times, serious divisions within the Bank of Englands Monetary Policy Committee make it more difficult for the bank to rebuild its credibility after five years of inflation exceeding its target.According to the Financial Times, investors are reducing their bets on Asian chipmakers.July 13 - Antengene (06996.HK) announced that it has received a US$60 million upfront payment from UCB for ATG-201. This upfront payment under the landmark agreement with UCB further strengthens the Groups cash position and provides strong financial support for advancing the Groups innovative drug pipeline and accelerating access for more patients.
